Unique characteristics of nanoparticles make them highly attractive for various applications in oncology. They are able to function as carriers for chemotherapeutic drugs to increase their therapeutic index and lower their toxicity, as therapeutic agents in photodynamic, gene, and thermal therapy, as well as molecular imaging agents to detect and monitor cancer progression. Several nanoparticle-based agents for cancer therapy and diagnostics have been approved by FDA, more are in clinical trials, and even more are in the discovery and early development stages in academic and industry laboratories. Cambridge Healthtech Institute’s Latest Advances in Nano-Oncology symposium is designed to encourage open discussion and knowledge exchange in this exiting and rapidly developing area at the junction of nanobiotechnology and oncology.
NBIC - Multidisciplinary scientific field at the crossroads of nanotechnologies (N), biotechnologies (B), information technology (I) and cognitive sciences (C).
